G

Galecto
D

GLTO

5.73300
USD
0.13
(2.38%)
Market Closed
Volume
0
EPS
-16
Div Yield
-
P/E
-0
Market Cap
7,550,298
OverviewSignalsIdeasNews
Related Instruments
    A
    ADMA
    -1.180
    (-5.84%)
    19.030 USD
    A
    ARDX
    0.25000
    (5.30%)
    4.96500 USD
    B
    BPMC
    -6.990
    (-7.31%)
    88.690 USD
    C
    CKPT
    -0.35000
    (-9.31%)
    3.41000 USD
    KHC
    KHC
    -0.645
    (-2.03%)
    31.135 USD
    K
    KOD
    0.25000
    (4.73%)
    5.54000 USD
    M
    MGNX
    -0.23000
    (-6.04%)
    3.58000 USD
    N
    NVCR
    -0.470
    (-2.83%)
    16.120 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    More
News

Title: Galecto Inc

Sector: Healthcare
Industry: Biotechnology
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.